Renovaro Management

Management criteria checks 1/4

Renovaro's CEO is David Weinstein, appointed in Oct 2024, has a tenure of less than a year. directly owns 0.16% of the company’s shares, worth €144.56K. The average tenure of the management team and the board of directors is 0.4 years and 3.3 years respectively.

Key information

David Weinstein

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.2%
Management average tenure	less than a year
Board average tenure	3.3yrs

Recent management updates

Recent updates

CEO

David Weinstein (64 yo)

less than a year

Tenure

Mr. David H. Weinstein, also known as David, is CEO & Director of Renovaro Inc. from October 14, 2024. Mr. Weinstein has extensive experience with U.S. securities and investment banking firms. He has been...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Simon Tarsh	Interim Chief Financial Officer	less than a year	US$330.33k	no data
Francois Binette	Executive VP for Research & Development	no data	US$430.29k	0% € 0
David Weinstein	CEO & Director	less than a year	no data	0.16% € 144.6k
Serhat Gümrükcü	Co-Founder & Inventor	no data	no data	11.12% € 10.2m
Greg Duczynski	Senior Vice President for Clinical Operations	2.6yrs	no data	no data

0.4yrs

Average Tenure

63yo

Average Age

Experienced Management: 2Q5's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
David Weinstein	CEO & Director	less than a year	no data	0.16% € 144.6k
James McNulty	Independent Director	less than a year	no data	no data
Richard Whitley	Member of Respiratory Diseases Scientific Advisory Board	3.3yrs	no data	no data
Anna Lok	Member of HBV Scientific Advisory Board	3.3yrs	no data	no data
Carol Brosgart	Chairperson of HBV Cure Scientific Advisory Board	4.3yrs	US$129.74k	0% € 0
Fabien Zoulim	Member of HBV Scientific Advisory Board	4.3yrs	no data	no data
Maurice Van Tilburg	Independent Director	less than a year	no data	no data
Mark Collins	Independent Director	less than a year	no data	no data
W. Hardy	Chairman of HIV Scientific Advisory Board	6.3yrs	no data	no data
Steven Deeks	Member of HIV Scientific Advisory Board	6.8yrs	no data	no data
Peter Revill	Member of HBV Scientific Advisory Board	4.3yrs	no data	no data
Geert Kazemier	Chairman of Scientific Advisory Board	less than a year	no data	no data

3.3yrs

Average Tenure

72yo

Average Age

Experienced Board: 2Q5's board of directors are considered experienced (3.3 years average tenure).

Renovaro Management

Management criteria checks 1/4

Key information

Recent management updates

Renovaro Inc. Announces CEO Changes

Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board

Renovaro Inc. Announces Board Changes

Renovaro Biosciences Inc. Appoints Avram Miller as Board of Directors

Renovaro Biosciences Inc. Appoints Leni Boeren and Ruud Hendriks as Independent Directors

Enochian Biosciences Inc., Annual General Meeting, Jun 22, 2023

Recent updates

Renovaro Inc. Announces CEO Changes

Renovaro Inc. announced delayed annual 10-K filing

Renovaro Receives Deficiency Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board

Renovaro Inc. Announces Board Changes

Renovaro Biosciences Inc. (NasdaqCM:RENB) completed the acquisition of GEDi Cube Intl Ltd.

Renovaro Biosciences Inc. contemplates bankruptcy.

Renovaro Biosciences Inc. contemplates bankruptcy.

Renovaro Biosciences Inc. Appoints Avram Miller as Board of Directors

Renovaro Biosciences Inc. Appoints Leni Boeren and Ruud Hendriks as Independent Directors

Renovaro Biosciences Inc. announced delayed annual 10-K filing

Renovaro Biosciences Inc. (NasdaqCM:RENB) signed a letter-of-intent to acquire GEDi Cube Intl Ltd.

Enochian Biosciences Inc. Receives Non-Compliance Letter from Nasdaq

Enochian Biosciences Inc.(NasdaqCM:ENOB) dropped from Russell Small Cap Comp Value Index

Enochian Biosciences Inc. Announces That Its Cancer Platform Remains on Track for Trials in Humans Following FDA Review

Enochian Biosciences Inc., Annual General Meeting, Jun 22, 2023

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for Period Ended September 30, 2022

Enochian Biosciences, Inc. announced delayed 10-Q filing

Enochian Biosciences Receives Notice from Nasdaq for Not Filing Form 10-K

Enochian Biosciences, Inc. announced delayed annual 10-K filing

Rosen Law Firm Encourages Enochian Biosciences Investors to Secure Counsel Before Important September 26 Deadline in Securities Class Action

Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Enochian Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Enochian Biosciences, Inc

Johnson Fistel, LLP Announces That A Class Action Lawsuit Commence on Behalf of Investors of Enochian Biosciences Inc

High number of new and inexperienced directors

High number of new directors

Enochian BioSciences Appoints Dr. François Binette, Ph.D. as Executive Vice President for Research and Development

Enochian Biosciences, Inc. Announces Appointment of Greg Duczynski as Senior Vice President for Clinical Operations

High number of new directors

Enochian Biosciences, Inc. Announces Resignation of Carl Sandler as Member of the Board of Directors

Enochian Biosciences, Inc., Annual General Meeting, Mar 14, 2022

High number of new directors

High number of new directors

Enochian Biosciences, Inc. Announces Its Successful Completion of FDA Pre-IND for A Potential Cure for Hepatitis B Virus Infection

High number of new directors

High number of new directors

High number of new directors

Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection

Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity

Enochian Biosciences, Inc.(NasdaqCM:ENOB) dropped from Russell 3000E Value Index

Enochian BioSciences, Inc. Announces FDA Acceptance of Pre-IND Request for Potential HIV Cure

New 90-day high: €3.74

Enochian Biosciences, Inc., Annual General Meeting, Mar 05, 2021

New 90-day high: €2.80

New 90-day low: €2.48

New 90-day low: €2.58

New 90-day low: €2.78

New 90-day low: €2.98

New 90-day low - €3.00

Enochian Biosciences, Inc.(NasdaqCM:ENOB) dropped from Russell 3000 Growth Index

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age